To further evaluate the clinical utility of ATX, we systematically compared it with both tumor markers (AFP, PIVKA‐2) and fibrosis markers (HA, 4C7S, FIB‐4, M2BPGi) for post‐RFA recurrence prediction. The gene discussed is ENPP2; the disease is neoplasm.